香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 氯維地平乳狀注射液獲藥品註冊批件 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團開發的氯維地平乳狀注射液(50ml: 25 mg、100ml: 50mg)（「該產品」）已獲得中華人 民共和國國家藥品監督管理局頒發的藥品註冊批件。 該產品是二氫吡啶類鈣通道阻滯拮抗劑，屬於速效靜脈降壓藥，適用於治療不適宜口服或 預期口服藥物治療效果不佳的高血壓患者。與臨床常用的治療藥物相比，該產品具有以下 顯 著 優 勢 ： 起 效 更 快 ， 可 實 現 血 壓 的 快 速 、 實 時 、 精 準 調 控 ； 更 適 用 於 肝 腎 功 能 異 常 患 者 ， 其 用 藥 期 間 無 需 調 整 劑 量 ； 使 用 時 無 需 稀 釋 配 製 ...

Group 1: Market Movements - Tencent Holdings saw a net buy of 1.304 billion, while Xiaomi Group-W had a net buy of 0.277 billion and China Life Insurance 0.187 billion [1] - Major net sell-offs included Hua Hong Semiconductor at 0.651 billion, Zijin Mining at 0.464 billion, and Alibaba-W at 0.328 billion [1] - Southbound funds have recorded net buys in Xiaomi for three consecutive days, totaling 1.8348 billion HKD, while China Mobile has seen net sells for 21 consecutive days, amounting to 16.04415 billion HKD [4] Group 2: Company Updates - Tencent's AI application "Yuanbao" has launched a cash red envelope activity with a total scale of approximately 1 billion, allowing users to participate in cash rewards and tasks [6] - Xiaomi delivered over 39,000 vehicles in January, marking a 95% year-on-year increase, and plans to open six new stores in February [7] - Alibaba's Qianwen App announced a 3 billion investment to launch the "Spring Festival Treat Plan," set to go live on February 6, aiming to enhance user engagement during the holiday [7]

Core Insights - On February 2, 2026, Alibaba-W (09988), Tencent Holdings (00700), and China Mobile (00941) were the top three companies by trading volume in the Southbound Stock Connect, with transaction amounts of 6.121 billion, 4.166 billion, and 3.225 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and SMIC (00981) also led the trading volume, with transaction amounts of 3.730 billion, 2.511 billion, and 2.012 billion respectively [1] Southbound Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 6.121 billion with a net buy of -0.816 billion [2] - Tencent Holdings (00700) recorded a trading amount of 4.166 billion with a net buy of +0.880 billion [2] - China Mobile (00941) had a trading amount of 3.225 billion with a net buy of -0.134 billion [2] - SMIC (00981) had a trading amount of 2.965 billion with a net buy of -29.8693 million [2] - Other notable companies included Xiaomi Group-W (01810) with a trading amount of 2.096 billion and a net buy of +0.391 billion [2] Shenzhen-Hong Kong Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 3.730 billion with a net buy of +0.488 billion [2] - Tencent Holdings (00700) recorded a trading amount of 2.511 billion with a net buy of +0.424 billion [2] - SMIC (00981) had a trading amount of 2.012 billion with a net buy of -1.32 billion [2] - Other significant companies included China Mobile (00941) with a trading amount of 1.401 billion and a net buy of +0.0651447 billion [2]

Market Overview - Southbound funds traded approximately HKD 138.285 billion today, a significant increase of about HKD 21.8 billion compared to the previous day, accounting for 39.75% of the total turnover of the Hang Seng Index, which has been below 40% for several consecutive days [2] - Despite the Hong Kong stock market accelerating downward, southbound funds saw a net inflow of approximately HKD 1.907 billion, with the Shanghai-Hong Kong Stock Connect recording a net inflow of about HKD 2.738 billion, while the Shenzhen-Hong Kong Stock Connect experienced a net outflow of approximately HKD 0.83 billion [2] Individual Stock Performance - Tencent Holdings (0700.HK) saw a significant net buy of HKD 1.304 billion, while its stock price fell by 1.24% [2][3] - Xiaomi Group-W (01810.HK) had a net buy of HKD 0.278 billion, with a stock price decline of 1.24% [2][3] - Huahong Semiconductor (01347.HK) experienced a net outflow of HKD 0.615 billion and a sharp decline of 11.24% [2][4] - Zijin Mining (02899.HK) had a net outflow of HKD 0.464 billion, with a stock price drop of 5.58% [2][4] - CSPC Pharmaceutical Group (01093.HK) saw a net outflow of HKD 0.393 billion and a decline of 4.69% [2][4] - Alibaba-W (09988.HK) experienced a net outflow of HKD 0.329 billion, with a stock price decrease of 3.49% [2][4] - SMIC (00981.HK) had a net outflow of HKD 0.162 billion, with a decline of 4.24% [2][4] Trading Activity - In the top ten active stocks on the Hong Kong Stock Connect (Shanghai), Alibaba-W had a net outflow of HKD 0.816 billion, while Tencent Holdings had a net inflow of HKD 0.880 billion [5] - On the Shenzhen Stock Connect, Alibaba-W recorded a net inflow of HKD 0.488 billion, while Huahong Semiconductor had a significant net outflow of HKD 0.554 billion [5]

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound capital, with a total net buy of HKD 19.07 billion on February 2, 2023, indicating strong investor interest in certain stocks while others faced net sell-offs [1]. Group 1: Northbound Capital Activity - Northbound capital recorded a net buy of HKD 27.38 billion through the Shanghai Stock Connect and a net sell of HKD 8.3 billion through the Shenzhen Stock Connect [1]. - The most bought stocks included Tencent (00700), Xiaomi Group-W (01810), and China Life (02628) [1]. - The most sold stocks were Hua Hong Semiconductor (01347), Zijin Mining (02899), and CSPC Pharmaceutical Group (01093) [1]. Group 2: Individual Stock Performance - Alibaba-W (09988) had a net sell of HKD 3.28 billion, with plans to invest HKD 30 billion in a "Spring Festival Treat Plan" [6][7]. - Tencent (00700) saw a net buy of HKD 13.03 billion, boosted by the launch of its "Yuanbao" Spring Festival red envelope activity, which is expected to increase downloads and user engagement [4]. - China Life (02628) received a net buy of HKD 1.87 billion, supported by positive forecasts for its individual insurance sales [5]. - Hua Hong Semiconductor (01347) faced a net sell of HKD 6.15 billion, amid tightening order reviews from major chip manufacturers [6]. - Zijin Mining (02899) experienced a net sell of HKD 4.64 billion, as it announced plans to issue USD 1.5 billion zero-coupon convertible bonds for project financing [7].

证券研究报告 行业研究 / 行业点评 2026 年 02 月 02 日 行业及产业 医药生物 一年内行业指数与沪深 300 指数对比走势： 资料来源：聚源数据，爱建证券研究所 相关研究 《医药行业跟踪报告：医药板块迎来开门红， 2026 年继续看好创新出海和硬科技》 2026-01-13 《2026 年度医药行业策略：创新出海新征程， 寻找需求新增量》2026-01-05 张智聪 S0820525020002 021-32229888-25524 zhangzhicong@ajzq.com ——医药行业跟踪报告 MNC 重金加码中国创新药，中国 IO2.0 双抗出海迈出关键一步 强于大市 投资要点： 医药板块行情复盘：本周（1/26~2/1）市场以震荡调整为主，SW 医药生物指数下跌 3.31%， 在申万一级行业指数中排名 22/31，跑输沪深 300 指数（+0.08%）；各细分板块中，血液 制品（-0.99%）、疫苗（-1.65%）表现相对较好，主要与尼帕病毒概念相关，部分 CXO 个 股由于业绩催化表现较为突出，线下药店（-4.83%）和医院（-4.47%）表现较弱。港股创新 药回调明显，恒生生物科技指 ...

Core Viewpoint - The recent leadership change at Newnoway, with a young manager taking over amidst significant financial losses, highlights the challenges faced by Chinese pharmaceutical companies in their transformation efforts [1][15]. Management Changes - Newnoway appointed Dai Long, a 1992-born executive, as the new general manager, who previously served as the board secretary and will also continue as the financial director [1][17]. - The former general manager, Yao Bing, will remain as the chairman [17]. - Dai Long's annual salary is only 223,200 yuan despite holding multiple positions, reflecting the company's current financial constraints [5][19]. Financial Performance - Newnoway expects a net loss of 170 million to 255 million yuan for 2025, marking a decline of 416% to 575% compared to the previous year, which will be the company's first annual loss since its listing in 2019 [15][20]. - The company's net profit dropped from 726 million yuan in 2022 to 43.4 million yuan in 2023, a decrease of 40.18%, and further to 5.37 million yuan in 2024, a decline of 87.63% [6][20]. - The decline in performance is attributed to increased R&D expenses, expanded losses from acquired subsidiaries, and decreased gross margins in traditional business lines [20][21]. Business Transformation - Newnoway is transitioning from traditional functional raw materials, primarily caffeine, to innovative pharmaceuticals, including antibody-drug conjugates and mRNA vaccines [10][24]. - The company acquired a 51% stake in Giant Stone Biotech in 2023 and increased its stake to 80% in 2025, but the subsidiary has not yet contributed positively to overall performance [10][24]. - The strategic partnership with AstraZeneca, potentially worth over $17 billion, offers a glimmer of hope for the company's innovative drug pipeline [12][25]. Challenges and Outlook - Newnoway faces the challenge of balancing its declining traditional business with the need for substantial investment in innovative drug development [13][25]. - As of the third quarter of 2025, the company's debt ratio rose to 32.94%, indicating increased financial pressure [13][25]. - The success of Dai Long's leadership will be critical in navigating these challenges and achieving a successful transition from a traditional raw material supplier to an innovative pharmaceutical company [26][27].

该行指，石药集团于去年5月公布将有3项潜在对外授权交易，是次协议应为第二项落实的交易，而落实 时间较预期延迟。由于协议中的资产处于早期阶段，该行未有将相关收入纳入预测，仅将协议首付款计 入预测，并将2026年收入及净利润预测分别上调27.9%及107.2%。 报告指，石药集团与阿斯利康合作达成协议，开发创新长效多肽药物，协议总价值最高可达185亿美 元。根据协议，石药将获得12亿美元的首付款，并有资格获得最高35亿美元的潜在研发里程碑付款，以 及最高138亿美元的潜在销售里程碑付款。 美银证券发布研报称，将石药集团(01093)目标价由8.5港元上调至9.1港元，但重申"跑输大市"评级，因 认为集团现有产品组合面临销售压力，且研发管线短期贡献有限，大多数关键资产仍处于早期阶段。 ...

美银证券发表研报指，石药集团与阿斯利康合作达成协议，开发创新长效多肽药物，协议总价值最高可 达185亿美元。根据协议，石药将获得12亿美元的首付款，并有资格获得最高35亿美元的潜在研发里程 碑付款，以及最高138亿美元的潜在销售里程碑付款。 该行指，石药集团于去年5月公布将有3项潜在对外授权交易，是次协议应为第二项落实的交易，而落实 时间较预期延迟。由于协议中的资产处于早期阶段，该行未有将相关收入纳入预测，仅将协议首付款计 入预测，并将2026年收入及净利润预测分别上调27.9%及107.2%。因此，该行将目标价由8.5港元上调至 9.1港元，但重申"跑输大市"评级，认为集团现有产品组合面临销售压力，且研发管线短期贡献有限， 大多数关键资产仍处于早期阶段。 ...

该行认为siRNA进入肥胖维持市场，将对所有胜肽类方案构成真正威胁。siRNA药物切入减重及肌保市 场，或最终挤压肽基肥胖疗法。该行密切追踪Arrowhead和Wave siRNA资产进展后，认为肥胖维持领域 正日益拥挤。建议投资人关注未来siINHBE和siALK7靶点对减重维持市场的影响。 招商证券国际发布研报称，石药集团(01093)与阿斯利康(AZN.US)达成历史性交易公告，表示看好交 易，但需等待石药或阿斯利康披露更多长效GLP-1全球开发细节。重申"中性"评级，认为短期基本面仍 存隐忧。 该行表示，根据石药最新公告，与阿斯利康合作的关键临床候选药物为SYH2082，长效GLP-1R/GIPR双 激动剂，现已进入I期临床。该行对此长效GLP-1平台了解甚少。SYH2082刚在中国启动I期研究。需等 待管理阶层揭露其设计细节及潜在临床开发路径，方能进行价值量化评估。该行维持"中国创新药进入 全球管线"的长期正面判断，但建议投资者仔细审视BD公告前已被市场计入预期的资产估值因素，并对 双方合作进展进行深度量化评估。 ...